NASDAQ:LMAT LeMaitre Vascular Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding LeMaitre Vascular Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $33.45 +0.95 (+2.92 %) (As of 09/23/2020 12:00 AM ET) Add Compare Share Today's Range$32.46Now: $33.45▼$33.8050-Day Range$28.38MA: $30.65▼$32.9652-Week Range$18.76Now: $33.45▼$38.64Volume216,578 shsAverage Volume136,334 shsMarket Capitalization$676.59 millionP/E Ratio41.30Dividend Yield1.17%Beta1.37 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.Read More Beat the Market (BTM) Rank™ 1.3 Analyst's Opinion Consensus RatingLeMaitre Vascular has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.14, LeMaitre Vascular has a forecasted downside of 0.9% from its current price of $33.45.Amount of Analyst CoverageLeMaitre Vascular has only been the subject of 3 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesLeMaitre Vascular has received 460 “outperform” votes. (Add your “outperform” vote.)Underperform VotesLeMaitre Vascular has received 332 “underperform” votes. (Add your “underperform” vote.)Community SentimentLeMaitre Vascular has received 58.08% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote “Outperform” if you believe LMAT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 1.7 Dividend Strength Dividend YieldLeMaitre Vascular has a dividend yield of 1.17%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthLeMaitre Vascular has only been increasing its dividend for 1 years.Dividend CoverageThe dividend payout ratio of LeMaitre Vascular is 43.18%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 37.62% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LeMaitre Vascular insiders have sold 127.14% more of their company's stock than they have bought. Specifically, they have bought $200,548.00 in company stock and sold $455,532.00 in company stock.Percentage Held by InsidersOnly 16.50% of the stock of LeMaitre Vascular is held by insiders.Percentage Held by Institutions83.61% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for LeMaitre Vascular are expected to grow by 31.17% in the coming year, from $0.77 to $1.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LeMaitre Vascular is 41.30, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.04.Price to Earnings Ratio vs. SectorThe P/E ratio of LeMaitre Vascular is 41.30, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.37.Price to Earnings Growth RatioLeMaitre Vascular has a PEG Ratio of 4.11. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLeMaitre Vascular has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.3Community Rank: 2.9Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.62 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LMAT Previous Symbol CUSIPN/A CIK1158895 Webwww.lemaitre.com Phone781-221-2266Debt Debt-to-Equity Ratio0.24 Current Ratio2.07 Quick Ratio1.03Price-To-Earnings Trailing P/E Ratio41.30 Forward P/E Ratio43.44 P/E Growth4.11 Sales & Book Value Annual Sales$117.23 million Price / Sales5.77 Cash Flow$1.24 per share Price / Cash Flow26.99 Book Value$7.41 per share Price / Book4.51Profitability EPS (Most Recent Fiscal Year)$0.88 Net Income$17.93 million Net Margins14.36% Return on Equity11.13% Return on Assets8.25%Miscellaneous EmployeesN/A Outstanding Shares20,227,000Market Cap$676.59 million Next Earnings Date10/28/2020 (Estimated) OptionableOptionable $33.45 +0.95 (+2.92 %) (As of 09/23/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive LMAT News and Ratings via Email Sign-up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter. LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions How has LeMaitre Vascular's stock price been impacted by COVID-19 (Coronavirus)? LeMaitre Vascular's stock was trading at $26.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LMAT stock has increased by 28.2% and is now trading at $33.45. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of LeMaitre Vascular? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for LeMaitre Vascular. When is LeMaitre Vascular's next earnings date? LeMaitre Vascular is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020. View our earnings forecast for LeMaitre Vascular. How were LeMaitre Vascular's earnings last quarter? LeMaitre Vascular Inc (NASDAQ:LMAT) posted its earnings results on Thursday, July, 23rd. The medical instruments supplier reported $0.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.01 by $0.16. The medical instruments supplier had revenue of $24.85 million for the quarter, compared to analyst estimates of $15.58 million. LeMaitre Vascular had a return on equity of 11.13% and a net margin of 14.36%. View LeMaitre Vascular's earnings history. How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular? LeMaitre Vascular declared a quarterly dividend on Monday, July 27th. Shareholders of record on Thursday, August 27th will be paid a dividend of $0.095 per share on Thursday, September 10th. This represents a $0.38 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date of this dividend is Wednesday, August 26th. View LeMaitre Vascular's dividend history. What guidance has LeMaitre Vascular issued on next quarter's earnings? LeMaitre Vascular updated its third quarter 2020 After-Hours earnings guidance on Thursday, July, 23rd. The company provided earnings per share (EPS) guidance of 0.17-0.26 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.08. The company issued revenue guidance of $30.5-34.5 million, compared to the consensus revenue estimate of $20.94 million. What price target have analysts set for LMAT? 7 Wall Street analysts have issued twelve-month price targets for LeMaitre Vascular's stock. Their forecasts range from $28.00 to $40.00. On average, they anticipate LeMaitre Vascular's stock price to reach $33.14 in the next year. This suggests that the stock has a possible downside of 0.9%. View analysts' price targets for LeMaitre Vascular. Who are some of LeMaitre Vascular's key competitors? Some companies that are related to LeMaitre Vascular include Inovio Pharmaceuticals (INO), NuVasive (NUVA), Shockwave Medical (SWAV), Merit Medical Systems (MMSI), Silk Road Medical (SILK), Glaukos (GKOS), Cantel Medical (CMD), Axonics Modulation Technologies (AXNX), AtriCure (ATRC), Cardiovascular Systems (CSII), Luminex (LMNX), Atrion (ATRI), Cerus (CERS), GenMark Diagnostics (GNMK) and Orthopediatrics (KIDS). View all competitors. What other stocks do shareholders of LeMaitre Vascular own? Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include Canopy Growth (CGC), AbbVie (ABBV), Sociedad Quimica y Minera de Chile (SQM), Gilead Sciences (GILD), NVIDIA (NVDA), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), salesforce.com (CRM), Adobe (ADBE) and Boeing (BA). Who are LeMaitre Vascular's key executives? LeMaitre Vascular's management team includes the following people: Mr. George W. LeMaitre, Chairman & CEO (Age 54)Mr. David B. Roberts, Pres & Director (Age 55)Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 54)Mr. Trent G. Kamke, Sr. VP of Operations (Age 48)Dr. George D. LeMaitre, Founder and Chairman of Scientific Advisory Board (Age 85) What is LeMaitre Vascular's stock symbol? LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT." Who are LeMaitre Vascular's major shareholders? LeMaitre Vascular's stock is owned by a variety of retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (8.93%), Vanguard Group Inc. (6.19%), Copeland Capital Management LLC (3.18%), Principal Financial Group Inc. (2.52%), Principal Financial Group Inc. (2.51%) and Russell Investments Group Ltd. (1.56%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, Lawrence J Jasinski, Michael H Thomas and Trent G Kamke. View institutional ownership trends for LeMaitre Vascular. Which institutional investors are selling LeMaitre Vascular stock? LMAT stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Vanguard Group Inc., Federated Hermes Inc., WINTON GROUP Ltd, Foundry Partners LLC, Goldman Sachs Group Inc., Cadence Capital Management LLC, and Principal Financial Group Inc.. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, and Trent G Kamke. View insider buying and selling activity for LeMaitre Vascular. Which institutional investors are buying LeMaitre Vascular stock? LMAT stock was purchased by a variety of institutional investors in the last quarter, including Tygh Capital Management Inc., Conestoga Capital Advisors LLC, Copeland Capital Management LLC, Sit Investment Associates Inc., Envestnet Asset Management Inc., Marshall Wace LLP, Engineers Gate Manager LP, and Raymond James Financial Services Advisors Inc.. View insider buying and selling activity for LeMaitre Vascular. How do I buy shares of LeMaitre Vascular? Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is LeMaitre Vascular's stock price today? One share of LMAT stock can currently be purchased for approximately $33.45. How big of a company is LeMaitre Vascular? LeMaitre Vascular has a market capitalization of $676.59 million and generates $117.23 million in revenue each year. The medical instruments supplier earns $17.93 million in net income (profit) each year or $0.88 on an earnings per share basis. What is LeMaitre Vascular's official website? The official website for LeMaitre Vascular is www.lemaitre.com. How can I contact LeMaitre Vascular? LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266. This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
